These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 9630825)

  • 1. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
    Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H; Echizen H
    Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
    Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
    Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K
    Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.
    Takahashi H; Wilkinson GR; Caraco Y; Muszkat M; Kim RB; Kashima T; Kimura S; Echizen H
    Clin Pharmacol Ther; 2003 Mar; 73(3):253-63. PubMed ID: 12621390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.
    Kimura M; Ieiri I; Mamiya K; Urae A; Higuchi S
    Ther Drug Monit; 1998 Jun; 20(3):243-7. PubMed ID: 9631918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
    Yamazaki H; Inoue K; Shimada T
    Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
    Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
    Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.
    Scordo MG; Pengo V; Spina E; Dahl ML; Gusella M; Padrini R
    Clin Pharmacol Ther; 2002 Dec; 72(6):702-10. PubMed ID: 12496751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
    Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
    Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H
    Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.
    Takahashi H; Sato T; Shimoyama Y; Shioda N; Shimizu T; Kubo S; Tamura N; Tainaka H; Yasumori T; Echizen H
    Clin Pharmacol Ther; 1999 Dec; 66(6):569-81. PubMed ID: 10613612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genetic polymorphism of the CYP2C subfamily].
    Chiba K
    Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):15-21. PubMed ID: 9755458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
    Yamazaki H; Shimada T
    Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
    Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
    Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
    Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
    Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
    Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
    Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.